Anavex Life Sciences Corp. - Common Stock (AVXL)

The CHMP issued a negative trend vote but postponed its final decision to December.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.

The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window.

Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's progression and long-term efficacy over 144 weeks.

The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.

After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said.

Anavex published data showing blarcamesine prevented amyloid-related brain damage in mice, supporting SIGMAR1 as a target for Alzheimer's prevention.

Anavex reported that early use of blarcamesine in Alzheimer's trials led to sustained cognitive and functional improvements over 4 years.

Check out the top five trending stocks on Stocktwits on Wednesday as U.S. equity markets recover after taking a breather on Tuesday.

Anavex's blarcamesine shows sustained cognitive and functional benefit in early Alzheimer's patients after four years of continuous treatment.